

**Study Number:** I94043  
**Test Type:** TOX  
**Route:** Dosing in Water  
**Species/Strain:** Mouse/B6C3F1/N

**I05: Clinical Observations Summary**  
**Test Compound:** Sodium Metavanadate  
**CAS Number:** 13718-26-8

**Date Report Requested:** 07/08/2021  
**Time Report Requested:** 14:33:42  
**Lab:** Burleson Research Technologies

**Study Number:** I94043  
**Study Gender:** Female  
**PWG Approval Date:** See web page for date of PWG Approval  
**Version:** v1.2.7

**Study Number:** I94043  
**Test Type:** TOX  
**Route:** Dosing in Water  
**Species/Strain:** Mouse/B6C3F1/N

**I05: Clinical Observations Summary**  
**Test Compound:** Sodium Metavanadate  
**CAS Number:** 13718-26-8

**Date Report Requested:** 07/08/2021  
**Time Report Requested:** 14:33:42  
**Lab:** Burlison Research Technologies

Female

Phase	Observation	Treatment Groups (ppm)						
		0	31.3	62.5	125	250	500	50 mg/kg CPS
SD	Alopecia Head; Bilateral	2 / 40 SD 14	3 / 40 SD 14	5 / 40 SD 7	2 / 40 SD 14	2 / 40 SD 0	4 / 40 SD 0	1 / 40 SD 0
SD	Alopecia Head	8 / 40 SD 14	6 / 40 SD 14	8 / 40 SD 7	9 / 40 SD 14	9 / 40 SD 7	6 / 40 SD 14	4 / 40 SD 14
SD	Bruising Abdomen	0 / 40	0 / 40	0 / 40	0 / 40	1 / 40 SD 21	0 / 40	0 / 40
SD	Bruising Dorsum	0 / 40	0 / 40	0 / 40	0 / 40	1 / 40 SD 21	0 / 40	0 / 40
SD	Coat Soiled Anus	0 / 40	0 / 40	0 / 40	0 / 40	0 / 40	0 / 40	1 / 40 SD 26
SD	Discolored Tip of Tail; Bilateral	0 / 40	0 / 40	0 / 40	1 / 40 SD 0	0 / 40	0 / 40	0 / 40
SD	Hunched	0 / 40	0 / 40	1 / 40 SD 27	0 / 40	0 / 40	4 / 40 SD 27	1 / 40 SD 26
SD	Limping Hind Paw; Severe	0 / 40	0 / 40	0 / 40	0 / 40	0 / 40	0 / 40	1 / 40 SD 26
SD	Missing Tip of Tail; Bilateral	0 / 40	0 / 40	0 / 40	1 / 40 SD 0	0 / 40	0 / 40	0 / 40
SD	Missing Tip of Tail	1 / 40 SD 0	0 / 40	1 / 40 SD 0	1 / 40 SD 0	0 / 40	0 / 40	1 / 40 SD 0

**Study Number:** I94043  
**Test Type:** TOX  
**Route:** Dosing in Water  
**Species/Strain:** Mouse/B6C3F1/N

**I05: Clinical Observations Summary**  
**Test Compound:** Sodium Metavanadate  
**CAS Number:** 13718-26-8

**Date Report Requested:** 07/08/2021  
**Time Report Requested:** 14:33:42  
**Lab:** Burleson Research Technologies

---

**Female**

---

Phase	Observation	Treatment Groups (ppm)						
		0	31.3	62.5	125	250	500	50 mg/kg CPS
SD	Piloerection	8 / 40 SD 23	8 / 40 SD 24	8 / 40 SD 22	12 / 40 SD 22	8 / 40 SD 22	8 / 40 SD 21	8 / 40 SD 22
SD	Wound Hind Paw; Left	0 / 40	0 / 40	0 / 40	0 / 40	0 / 40	0 / 40	1 / 40 SD 26

---

**Study Number:** I94043  
**Test Type:** TOX  
**Route:** Dosing in Water  
**Species/Strain:** Mouse/B6C3F1/N

**I05: Clinical Observations Summary**  
**Test Compound:** Sodium Metavanadate  
**CAS Number:** 13718-26-8

**Date Report Requested:** 07/08/2021  
**Time Report Requested:** 14:33:42  
**Lab:** Burleson Research Technologies

#### LEGEND

---

Animals exhibiting clinical observations "within normal limits" were recorded as scheduled but are omitted from the table for clarity.

Upper row displays cumulative number of animals with observation / total animals started on study for SD days, total number of pregnant animals for GD days, or total number of littered females for LD days.

Lower row displays day of observation onset

SD – Study Day

CPS = Cyclophosphamide

**\*\* END OF REPORT \*\***